Bioelectronic Devices Capture and Release Tumor Cells for Early Cancer Diagnosis
|
By LabMedica International staff writers Posted on 11 Sep 2023 |

Metastasis, the spread of cancer cells from the primary tumor to distant organs, is the main cause of cancer-related deaths. Metastasis occurs when a cancer cell detaches from the initial tumor, travels through the bloodstream and lymphatic system, and invades other parts of the body. Collecting these circulating tumor cells non-invasively is crucial for understanding cell biology, as well as for cancer diagnosis, prognosis, and drug development. Traditional methods for gathering these cells in a usable form are time-consuming, given that the concentration of these cells in the bloodstream is incredibly low compared to other cell types.
Now, a group of researchers at the University of the Basque Country (UPV/EHU, Leioa, Spain) has designed a bioelectronic device that could revolutionize this process. The device featuring gold electrodes coated with a smart polymer not only captures but also releases cells in a controllable, non-destructive manner, while simultaneously tracking these activities through standard electrical readings. This is seen as a foundational step toward creating universal systems for early cancer detection. Previous biosensors designed for this purpose were less than ideal because they damaged cells during the capture and release process. To address this, the team integrated smart materials with bioelectronics, which involves the use of carbon-based semiconductors, for more accurate and less harmful cell capture and release mechanisms.
In their preliminary tests, the researchers did not use real patient samples but instead relied on commercial cells sustained in culture media. The results demonstrated that the device successfully captured and released these cells. The team is now in the process of customizing the polymer to interact specifically with different types of cells. Currently, the device is being used on esophageal cancer patient samples. Its role is to selectively accumulate cancer cells, making it easier to determine their concentration in the sample.
“We wanted to come up with a device capable of concentrating cancer cells in order to detect their concentration,” said Janire Sáez, Ikerbasque research professor in the UPV/EHU’s Microfluidics Cluster Group. These are the first steps towards developing platforms for cancer screening. This could be a good step forward because they generally involve low-cost technologies and can be mass-produced. The idea is to use this type of technology for early cancer diagnosis.”
Related Links:
UPV/EHU
Latest Technology News
- AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
- AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
- AI Model Achieves Breakthrough Accuracy in Ovarian Cancer Detection
- Portable Biosensor Diagnoses Psychiatric Disorders Using Saliva Samples
- Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement

- Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
- Viral Biosensor Test Simultaneously Detects Hepatitis and HIV
- Acoustofluidic Device to Transform Point-Of-Care sEV-Based Diagnostics
- AI Algorithm Assesses Progressive Decline in Kidney Function
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channelRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channelAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








